LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited announced that its SPONTAN® Nasal Spray for erectile dysfunction shows promising clinical study results, with faster absorption and onset of action than oral PDE5 inhibitors, while also demonstrating a better safety profile. The nasal spray reached maximum drug concentration at half the dosage and in significantly less time, averaging 12 minutes compared to 56 minutes for oral treatments, indicating potential to disrupt the global PDE5 inhibitor market. These positive outcomes will support regulatory filings in the United States and other key international markets.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
